On this page
SIRT6 is a nuclear enzyme that keeps DNA intact, silences inflammatory genes, and — in mice engineered to make more of it — extends lifespan. It also declines with age, and further in Alzheimer's disease. This is what the evidence actually says, without the supplement-industry gloss.
What is SIRT6?
SIRT6 (short for sirtuin 6) is one of seven sirtuins in the human body. Sirtuins are enzymes that use NAD+ as a fuel to modify other proteins. Some sit in the mitochondria. Some sit in the nucleus. SIRT6 sits mainly in the nucleus, on your chromosomes.
The SIRT6 gene lives on chromosome 19. Every cell in your body carries a copy. It gets expressed in almost every tissue that's been mapped — colon, spleen, brain, liver, kidney, heart, and muscle.
What makes SIRT6 stand out is what it does with NAD+. It removes chemical tags from other proteins, changes how tightly your DNA is packaged, and controls which genes get read. That single job connects it to almost everything ageing biology cares about — DNA repair, inflammation, glucose control, and lifespan itself [1].
For the deep biochemistry, see our article on SIRT6 mechanism and structure.
What does SIRT6 do inside the cell?
SIRT6 does three main jobs. All three depend on NAD+.
Job one: SIRT6 removes acetyl tags from histones
Histones are the proteins your DNA wraps around. Small chemical tags called acetyl groups sit on histones and control how tightly the DNA is wound. Tightly wound DNA is silent. Loosely wound DNA gets read.
SIRT6 removes those tags from specific spots — histone H3 at positions K9, K56, and K18. When it does this, it silences retrotransposons, protects telomeres (the caps on your chromosomes), and stops runaway inflammation [2].
Job two: SIRT6 tags other proteins with ADP-ribose
Some sirtuins can transfer a bulky chemical group called ADP-ribose onto other proteins. SIRT6 is one of them. Its main target is PARP1 — the enzyme that flags broken DNA for repair. When SIRT6 tags PARP1, it makes PARP1 more efficient. The result is faster, cleaner repair of DNA damage [3].
Job three: SIRT6 needs NAD+ to work
Every one of those reactions burns through NAD+. If your NAD+ levels drop, SIRT6 slows down. NAD+ falls with age. That's one reason SIRT6 activity falls with age too.
None of this is rare among sirtuins — SIRT1 through SIRT7 all depend on NAD+. What makes SIRT6 different is where it sits (on chromatin) and what it silences (retrotransposons, telomeric regions, inflammatory genes). For a side-by-side breakdown, see SIRT1 vs SIRT3 vs SIRT6.
How does SIRT6 protect DNA?
Every cell in your body takes tens of thousands of small hits of DNA damage per day — from oxygen, radiation, and ordinary metabolism. SIRT6 sits at the site of that damage and helps fix it.
Base excision repair
The most common type of DNA damage is a single wrong base. Base excision repair cuts the wrong base out and puts the right one in. Mice without SIRT6 cannot run this pathway properly. Their genomes fill up with errors, and they die of a progeroid syndrome within about four weeks of birth [1].
Double-strand break repair
The most dangerous type of DNA damage is a break that snaps the double helix in two. SIRT6 helps hold the broken ends together and recruits the enzymes that seal them back [3]. It also modifies chromatin around the break so the repair machinery can get in.
Why long-lived species do this better
In 2019, a comparative study looked at 18 rodent species — from short-lived mice to the naked mole rat, which lives up to 40 years. The long-lived species had more efficient DNA repair. When researchers swapped the SIRT6 protein from a long-lived species into a short-lived species' cells, repair got better. When they went the other way, repair got worse. SIRT6 is one of the specific molecules that separates a short-lived rodent from a long-lived one [4].
Telomere protection
SIRT6 also patrols the ends of your chromosomes — the telomeres. It removes acetyl tags from histones sitting on telomeric DNA, keeping the telomere caps stable [2]. Without SIRT6, telomeres shorten and break faster, and cells stop dividing sooner.
For the deep dive, see SIRT6 and DNA repair.
What do SIRT6 lifespan studies actually show?
This is where the SIRT6 story gets exciting and where it needs the most honest framing.
Kanfi 2012 — the male mouse study
In 2012, a Nature paper reported that mice genetically engineered to make extra SIRT6 lived roughly 15 to 16 per cent longer than normal mice. The catch: the effect only showed up in male mice. Female mice with the same genetic tweak lived a normal lifespan [5].
That single result put SIRT6 on the longevity map. It also raised a question nobody has fully answered: why males?
Roichman 2021 — the healthspan version
Nine years later, the same lab published a follow-up. This time, extra SIRT6 activity improved healthspan — physical function, glucose control, metabolic markers — in both sexes. Lifespan extension in females was smaller than in males, but the healthspan gains were real for both [6].
The mechanism traced to energy homeostasis. Extra SIRT6 meant the mice managed fuel better as they aged.
Nagar 2026 — reversing chromatin ageing in old animals
The most recent paper, published in Nature Communications, took aged wild-type mice and used gene therapy to boost SIRT6 in the liver. Chromatin ageing markers reversed. Gene expression patterns shifted back toward the young state [7].
This is the first study to show that a SIRT6 boost late in life — not lifelong genetic overexpression — can push a tissue back toward youth. It was done in mouse liver, not in humans.
The honest read
Every one of these studies uses genetic overexpression. None of them tests a supplement. The gap between "SIRT6 activity extends healthspan in transgenic mice" and "taking a SIRT6 activator will extend your lifespan" is enormous. The mouse work is a promising signal — not a licence to over-promise.
For the full lifespan literature, see SIRT6 longevity research.
What do we know about SIRT6 in humans?
Human SIRT6 evidence falls into three buckets: expression data, a rare genetic variant, and the absence of clinical trials.
Where SIRT6 is expressed
SIRT6 is expressed in almost every human tissue that has been mapped. Highest levels sit in the colon, spleen, and other epithelial and immune tissues. The brain expresses it at moderate levels, with cortical and hippocampal regions coming out on top.
Levels drop with age. In aged human brains, SIRT6 is lower than in younger brains. In Alzheimer's brains, it is lower still [8].
The centenarian variant
In 2022, a research group sequenced SIRT6 in a small cohort of centenarians — people who lived past 100. They found a rare double mutation, N308K plus A313S, enriched in the long-lived group. In cell studies, the centenarian variant did SIRT6's jobs better than the standard version, especially at maintaining genome stability [9].
The genetic enrichment was not statistically significant, because the cohort was too small. But the biochemistry is real: the centenarian SIRT6 works better.
What is missing: RCT evidence
No randomised controlled trial of a SIRT6 activator has been published in humans. There are no dose-finding studies, no long-term safety data, and no lifespan or healthspan endpoints. Every claim about "SIRT6 activation" on a supplement label rests on preclinical work.
That is not damning — the supplement class is genuinely early. But it should shape how you weigh the marketing.
Why does SIRT6 matter for the ageing brain?
The brain is where SIRT6's story gets particularly interesting.
The brain-specific knockout mouse
When SIRT6 is deleted only from mouse neurons, DNA damage accumulates in the cortex. Cells commit apoptosis. The Tau protein — the same protein that tangles in Alzheimer's disease — becomes hyperphosphorylated and hyperacetylated [8]. That is a striking overlap with human neurodegenerative pathology.
The mitochondrial connection
A 2023 study went deeper. It showed that SIRT6 loss in the brain crashes mitochondrial function — the energy factories that neurons rely on more than any other cell type. Oxidative phosphorylation drops. Reactive oxygen species climb. The gene expression signature of a SIRT6-deficient mouse brain overlaps directly with the signature of human Alzheimer's, Parkinson's, Huntington's, and ALS brains [10].
That does not prove SIRT6 loss causes these diseases. It does suggest the pathway matters and deserves further study.
Why the brain is uniquely vulnerable
Neurons have a high energy demand and limited ability to divide. That combination makes them particularly sensitive to any enzyme that maintains DNA integrity and mitochondrial output — which describes SIRT6.
For the clinical picture, see SIRT6, the brain, and Alzheimer's disease.
Can you increase SIRT6 naturally?
The honest answer is: partially, and none of the levers has been proven to raise SIRT6 in a human clinical trial.
Lifestyle levers
Three lifestyle inputs have mechanistic support: caloric restriction, exercise, and sleep. All three influence NAD+, and NAD+ fuels SIRT6.
None of these has been tested with SIRT6 as the primary endpoint in humans [11]. They are supported by mouse work and by adjacent human trials on NAD+ and sirtuin activity generally.
The deep dive is on how to increase SIRT6 naturally.
Foods that may activate SIRT6
The most-studied dietary SIRT6 activator is cyanidin — a purple-red pigment in black rice, blackcurrants, elderberries, and bilberries. In cell studies, cyanidin activates SIRT6 more potently than any other flavonoid tested.
Blueberries and purple corn contribute too, though at lower cyanidin content. The full list is on foods that boost SIRT6.
Does resveratrol activate SIRT6?
Resveratrol is famous for activating SIRT1. Its evidence for SIRT6 activation is much weaker. Some cell studies show a mild effect at high doses. Nothing in humans.
If SIRT6 is your target, resveratrol is not the shortest path. Cyanidin has better preclinical support. See polyphenol SIRT6 activators for the compound-by-compound breakdown.
Small-molecule activators
Several synthetic activators exist — MDL-800, MDL-811, UBCS039, and SP-624 (also called forvisirvat). All are preclinical for the longevity indication. Only SP-624 has entered human trials, and not yet for lifespan or healthspan endpoints. See SIRT6 gene therapy, peptides, and inhibitors.
Fucoidan — the emerging natural activator
A 2025 preprint from the Robbins lab reported that fucoidan — a sulphated polysaccharide from brown seaweed — extends lifespan in aged wild-type mice via SIRT6-dependent DNA repair [12]. This paper has not been peer-reviewed at the time of writing, so treat the findings as preliminary.
Fucoidan is what DoNotAge uses in their SIRT6 Activator product. The full evidence sits in our article on fucoidan as a SIRT6 activator.
What we still don't know about SIRT6
Every honest overview of a fast-moving science has to name its gaps. Here are the ones that matter for SIRT6.
- No human RCT of any SIRT6 activator has been published. Every dose recommendation, every efficacy claim, and every safety claim on a supplement label rests on preclinical work [11].
- Whether pharmacological SIRT6 activation produces the same benefit as genetic overexpression is unknown. A transgenic mouse gets more SIRT6 protein in every cell from birth. A supplement gets you a small molecule in circulation for a few hours a day.
- The male-only lifespan finding of the 2012 mouse study has never been fully explained. Later work suggests healthspan benefits may cross sexes, but the sex-specific lifespan question is open [5] [6].
- Dose, timing, and interactions for supplement activators like fucoidan and cyanidin have no human trial support. Everything sold as a SIRT6 activator today is a bet on translation.
- Whether raising SIRT6 activity in older adults is safe long-term is unknown. A 2022 review catalogued SIRT6 as a clear tumour suppressor in some cancers (bladder, nasopharyngeal, glioma), a clear oncogene in others (osteosarcoma, papillary thyroid), and context-dependent — varying by tumour stage or cell line — in melanoma, breast, lung, pancreatic, liver, prostate, colon, ovarian, and blood cancers [13]. See our article on SIRT6 and cancer for the full nuance.
None of this is a reason to write off SIRT6 as a target. It is a reason to weigh the claims carefully. Our SIRT6 Data Center tracks every paper we cite, so you can read the primary sources yourself.
Bottom line
SIRT6 is one of the most compelling molecular targets in ageing biology. The mouse and cell work is deep. The human evidence is genetic, observational, and preclinical.
Supplements that claim to activate SIRT6 are an early class. They are worth watching, not yet worth over-committing to.
If you want to do something today that has a plausible link to SIRT6 activity, the boring answer is the honest one: sleep enough, exercise regularly, eat dietary polyphenols (blueberries, blackcurrants, black rice, olives), and avoid excess calories. These are the levers with the most human data behind them.
The SIRT6 activator class is one to track over the next few years — not to bet on today.